必要な CMO / CDMO を検索して見つける
貴社の医薬品開発および製造プロジェクトのための高度なスキルを持つパートナーを見つけてください。
市場: EMA (EU), FDA (USA)
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, IFS, EMA (EU GMP)
バッチサイズ: Large, Small, Medium
カテゴリ / 製品: 化粧品, 栄養補助食品, FDF / 医薬品
使用: Human, Veterinary
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
OEB (職業性暴露バンディング): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
市場: EMA (EU), ANVISA (Brazil), Russian Health Authorities, SFDA (Saudi Arabia)
地域: ヨーロッパ
コンプライアンス: ISO, Roszdravnadzor (Russia GMP), SFDA (Saudi Food & Drug Authority), EMA (EU GMP)
バッチサイズ: Large, Small, Medium
カテゴリ / 製品: 化粧品, FDF / 医薬品
使用: Human, Veterinary
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging
地域: ヨーロッパ
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), MHRA (UK)
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, EMA (EU GMP)
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
サービス: Development services, Manufacturing services, Analytical / QC services
治療専門分野 (ATC): (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (N) Nervous system
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
カテゴリ / 製品: FDF / 医薬品
市場: EMA (EU), FDA (USA)
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)
バッチサイズ: Large, Small, Medium
カテゴリ / 製品: 栄養補助食品, サービス, 粒子工学
使用: Human, Veterinary
BSL (生物学的安全性レベル): 1, 2
サービス: Development services, Manufacturing services
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), Russian Health Authorities, MHRA (UK), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, TGA (Australia)
地域: ヨーロッパ
バッチサイズ: Large, Small, Medium
使用: Human
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging
治療専門分野 (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (A) Digestive tract and metabolism
コンプライアンス: PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TGA (Australia GMP), TITCK (Turkish Health Authorities), SFDA (Saudi Food & Drug Authority), EMA (EU GMP), Health Canada (Canada GMP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)
OEB (職業性暴露バンディング): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
カテゴリ / 製品: サービス, FDF / 医薬品
Adragos Pharma | Maisons-Alfort
Adragos Pharma
プレフィルドシリンジ、液体および凍結乾燥バイアルに特化し、高度な無菌充填、凍結乾燥、および検査システムを組み合わせています。
治療専門分野 (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (A) Digestive tract and metabolism
市場: EMA (EU), NMPA (China), ANVISA (Brazil), Russian Health Authorities, SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities
地域: ヨーロッパ
バッチサイズ: Large
使用: Human
BSL (生物学的安全性レベル): 1
サービス: Manufacturing services, Analytical / QC services, Regulatory services, Packaging
規制物質: Lowest potential for abuse
コンプライアンス: ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), SFDA (Saudi Food & Drug Authority), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)
カテゴリ / 製品: FDF / 医薬品
OEB (職業性暴露バンディング): 1 / low-hazard (PDE > 10,000 µg/day)
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), NMPA (China), MHRA (UK), MFDS (South Korea)
サービス: Logistics, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: ヨーロッパ
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
コンプライアンス: EMA (EU GMP)
カテゴリ / 製品: FDF / 医薬品
Adragos Pharma | Halden
Adragos Pharma
当社は、ブローフィルシール (BFS) 技術やその他の剤形を使用した IV バッグ、プラスチック製アンプル、バイアルの製造を専門としています。
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), ANVISA (Brazil), MHRA (UK), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), TGA (Australia)
サービス: Logistics, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), TGA (Australia GMP), TITCK (Turkish Health Authorities), UAE Ministry of Health & Prevention, NMPA (China GMP), EMA (EU GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP), NSF
バッチサイズ: Large, Small, Medium
使用: Human
治療専門分野 (ATC): (D) Dermatologicals, (V06) Nutrients, (A) Digestive tract and metabolism
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
カテゴリ / 製品: FDF / 医薬品
OEB (職業性暴露バンディング): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), ANMAT (Argentina), SFDA (Saudi Arabia), MFDS (South Korea), EDE (UAE), CDSCO (India), TGA (Australia)
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), UAE Ministry of Health & Prevention, NMPA (China GMP), EMA (EU GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP), NSF
バッチサイズ: Large, Small, Medium
使用: Human
カテゴリ / 製品: サービス, FDF / 医薬品
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), MHRA (UK), SFDA (Saudi Arabia), MFDS (South Korea), EDE (UAE), CDSCO (India), TGA (Australia)
サービス: Logistics, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: アジア太平洋
コンプライアンス: FDA (cGMP), PMDA/MHLW (Japan GMP), EMA (EU GMP)
バッチサイズ: Large
使用: Human
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
カテゴリ / 製品: サービス, FDF / 医薬品
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), MHRA (UK), MFDS (South Korea)
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), EMA (EU GMP)
使用: Human
規制物質: High potential for abuse & no medical use
バッチサイズ: Small, Medium
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
カテゴリ / 製品: FDF / 医薬品